ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-throughput sequencing has advanced biomarker identification, enabling more targeted cancer treatment. Various gene panels are used to screen for actionable genomic alterations for clinical practice and trial inclusion.
objectivesWe aimed to determine the proportion of cancer patients with a targetable molecular tumor alteration and their inclusion in related trials using a routine panel, and to compare these proportions with results from a larger panel combined with molecular tumor board (MTB) discussion.
designWe analyzed eligibility and inclusion in targeted therapy trials among all cancer patients treated at Poitiers University Hospital who underwent routine NGS.
methodsClinical trials were identified via the French National Cancer Institute (INCa) and ClinicalTrials.gov databases. Inclusion rates were also assessed for patients analyzed with the broader FoundationOne CDx® (FO) panel.
resultsAmong 1456 patients, 835 targetable mutations were identified: KRAS 43.6%, BRAF 19.0%, and PIK3CA 10.8%. Of 179 patients eligible for a dedicated trial, 19 were enrolled (10.6%), mostly at Poitiers University Hospital (84.2%) and predominantly melanoma patients (11/19). For 78.8% of non-included eligible patients, reasons were undocumented. FO analysis increased actionable alteration detection from 34.0% to 64.0%, with trial inclusion rising from 12.0% to 16.0%.
conclusionAlthough a substantial fraction of patients harbored actionable alterations, trial inclusion remained low at our center. Improving access requires better physician awareness of available clinical trials to optimize patient enrollment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.